Lost .I don’t think a lot of investors realize that .
1.That Acadia just needs to replicate the same results Neuren achieved in the Phase 2 results which were going for 6 weeks and continued to improve the longer they went .
2. Acadia has spent over $130 mill on Phase 3 trial so far .
3. The Phase 3 trials have been better targeted than the Phase 2 results .
4. Being an orphan drug the FDA is more receptive in getting the drug to market as at this stage there are no drugs available to help with retts syndrome .
2021, page-25
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
-0.050(0.36%) |
Mkt cap ! $1.757B | |||
| Open | High | Low | Value | Volume |
| $13.85 | $14.08 | $13.46 | $1.256M | 91.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 188 | $13.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.71 | 595 | 11 |
View Market Depth
| Last trade - 10.34am 10/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |